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Synthetic triterpenoid induces  
15-PGDH expression and suppresses  
inflammation-driven colon carcinogenesis
Sung Hee Choi,1 Byung-Gyu Kim,1 Janet Robinson,1 Steve Fink,2 Min Yan,2 Michael B. Sporn,3 
Sanford D. Markowitz,2 and John J. Letterio1
1Department of Pediatrics, Case Comprehensive Cancer Center, Case Western Reserve University,  
The Angie Fowler Adolescent and Young Adult Cancer Institute, Cleveland, Ohio, USA. 2Department of Medicine and Case Comprehensive Cancer Center,  
Case Western Reserve University and Case Medical Center, Cleveland, Ohio, USA. 3Department of Pharmacology,  
Dartmouth Medical School, Hanover, New Hampshire, USA.
Colitis-associated colon cancer (CAC) develops as a result of inflammation-induced epithelial transforma-
tion, which occurs in response to inflammatory cytokine-dependent downregulation of 15-hydroxypros-
taglandin dehydrogenase (15-PGDH) and subsequent suppression of prostaglandin metabolism. Agents that 
both enhance 15-PGDH expression and suppress cyclooxygenase-2 (COX-2) production may more effectively 
prevent CAC. Synthetic triterpenoids are a class of small molecules that suppress COX-2 as well as inflamma-
tory cytokine signaling. Here, we found that administration of the synthetic triterpenoid 2-cyano-3,12-dioxo-
oleana-1,9(11)-dien-C28-methyl ester (CDDO-Me) suppresses CAC in mice. In a spontaneous, inflammation-
driven intestinal neoplasia model, deletion of Smad4 specifically in T cells led to progressive production of 
inflammatory cytokines, including TNF-α, IFN-γ, iNOS, IL-6, IL-1β; as well as activation of STAT1 and STAT3; 
along with suppression of 15-PGDH expression. Oral administration of CDDO-Me to mice with SMAD4- 
deficient T cells increased survival and suppressed intestinal epithelial neoplasia by decreasing production of 
inflammatory mediators and increasing expression of 15-PGDH. Induction of 15-PGDH by CDDO-Me was 
dose dependent in epithelial cells and was abrogated following treatment with TGF-β signaling inhibitors 
in vitro. Furthermore, CDDO-Me–dependent 15-PGDH induction was not observed in Smad3–/– mice. Simi-
larly, CDDO-Me suppressed azoxymethane plus dextran sodium sulfate–induced carcinogenesis in wild-type 
animals, highlighting the potential of small molecules of the triterpenoid family as effective agents for the 
chemoprevention of CAC in humans.
Introduction
Epidemiologic data have shown an increasing burden of inflam-
matory bowel disease (IBD), with an estimated 1.7 million individ-
uals in the United States suffering from IBD and IBD-associated 
conditions (1–3). The 2 major subtypes, including ulcerative col-
itis and Crohn’s disease, are characterized by chronic, relapsing 
inflammation of the gastrointestinal tract (4, 5). Uncontrolled 
intestinal inflammation is characterized by overproduction of 
inflammatory cytokines and trafficking of effector leukocytes 
into the intestinal mucosal microenvironment. In humans, IBD 
ranks among the top 3 high-risk conditions for colorectal cancer, 
and affected individuals have a 10-fold greater risk of colon can-
cer over age-matched controls (6). Under homeostatic conditions 
in the intestinal mucosa there is a state of “controlled” immune 
cell activation and response in which there is a balance between 
proinflammatory (TNF-α, IFN-γ, IL-1, IL-6, and IL-12) and anti-
inflammatory cytokines (IL-4, IL-10, and TGF-β). Unchecked 
expression of proinflammatory cytokines, chemokines, and other 
chemical mediators underlies the chronic inflammatory state 
found in IBD (7–9). These proinflammatory cytokines are impli-
cated in inflammation-associated gastrointestinal tumorigenesis 
through their capacity to activate NF-κB, AP-1, STAT1, and 
STAT3 transcription factors, thereby promoting epithelial cell 
proliferation, survival, invasion, and metastasis.
The enzyme NAD-dependent 15-hydroxyprostaglandin dehydro-
genase (15-PGDH) plays a major role in catabolism of the nat-
urally occurring prostaglandin E2 by oxidizing the 15-hydroxyl 
group of prostaglandins to inactive 15-keto metabolites (10, 11). 
The human PGDH gene is located on chromosome 4 and encodes 
a 29-kDa protein. 15-PGDH is highly expressed in normal colon 
epithelia but the expression is decreased in colon cancers (12–15). 
15-PGDH has a demonstrated tumor suppressor activity in lung 
cancer and breast cancer (16, 17), and overexpression of 15-PGDH 
inhibits growth of colon tumor xenografts in immune-deficient 
mice (13). Expression of 15-PGDH is induced in colon epithelial 
cells by treatment with TGF-β, a cytokine known to activate an 
important tumor suppressor pathway in colon cancer (13, 18, 19). 
However, the mechanisms underlying this induction of 15-PGDH 
by TGF-β have not been defined clearly.
Recent studies have demonstrated the role of inflammatory 
cytokines in the suppression of 15-PGDH expression in IBD. For 
example, work by Otani and colleagues revealed that 15-PGDH 
protein and mRNA are markedly reduced in the inflamed 
mucosa of patients with IBD (20). This phenomenon was 
attributed to the actions of TNF-α, which suppressed transcrip-
tion of 15-PGDH in human colonocytes, while inducing COX-2 
and microsomal prostaglandin E synthase-1. In a more recent 
study, hemokinin-1, a tachykinin produced by immune cells and 
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upregulated in IBD, was shown to stimulate COX2 gene expres-
sion and repress 15-PGDH protein expression in colonic mucosal 
explants (21). COX-2 induction was coupled with hemokinin-1–
induced downregulation of PGDH mRNA and protein expression, 
suggesting again that hemokinin-1 may interfere with the down-
stream metabolism of prostaglandin E2 by suppressing 15-PGDH 
expression in the setting of IBD (21).
The synthetic oleanane triterpenoid 2-cyano-3,12-dioxo olean- 
1,9-dien-28-olic acid (CDDO) and its derivatives are small mol-
ecules with potent antiinflammatory and anticarcinogenic prop-
erties (22–29). The synthetic triterpenoids inhibit expression of 
inflammatory mediators, such as inducible NOS (iNOS) and 
inducible cyclooxygenase-2 (COX-2), through suppression of var-
ious inflammatory cytokines, such as IFN-γ, IL-1β, and TNF-α 
(30, 31), and also by direct inhibition of the signaling intermedi-
ate STAT3 (32). Synthetic triterpenoids have also been shown to 
enhance TGF-β/SMAD signaling by prolonging expression of the 
receptor-activated p-SMAD2 through enhanced cell surface TGF-β 
type II receptor expression (31, 33).
Here, we provide the first evidence that oral administration of 
a triterpenoid potently suppresses colitis-associated colon cancer 
(CAC) in mice. We show that oral administration of the synthetic 
triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-C28-methyl 
ester (CDDO-Me) markedly increased survival, reduced inflam-
mation, and inhibited spontaneous colon tumorigenesis in mice 
with a T cell–restricted deletion of the TGF-β signaling interme-
diate, SMAD4 (Lck-Cre Smadco/co [Smad4Tko] mice) (34), and in wild-
type mice, which were tested with a classical model of carcinogen-
esis that combines the carcinogen azoxymethane (AOM) and an 
inducer of inflammation, dextran sodium sulfate (DSS). CDDO-
Me administration suppressed the production of proinflamma-
tory cytokines and proinflammatory mediators such as iNOS 
and restored the expression of 15-PGDH in intestinal epithelia. 
Furthermore, we show the induction of 15-PGDH by CDDO-Me 
in vivo is absent in mice with a germ line deletion of the Smad3 gene 
(Smad3–/– mice) and is abrogated by inhibitors of TGF-β signaling 
in vitro. These data support the further development of this class 
of small molecules as potent, safe, and effective agents for the 
chemoprevention of CAC.
Results
Loss of 15-PGDH expression, induction of COX-2 and iNOS, and acti-
vation of STAT signaling are all hallmarks of CAC in the Smad4Tko 
mice. We previously established a novel murine model of CAC 
through creation of a T cell–specific deletion of the Smad4 gene 
in mice (34). In this model, selective loss of SMAD4-dependent 
signaling in T cells leads to spontaneous intestinal inflammation 
throughout the gastrointestinal tract. Smad4Tko mice invariably 
develop CAC after 8 months of age, with inflammatory infiltra-
tion of the mucosa, loss of body weight, and bloody diarrhea. We 
hypothesized that the development of CAC in this model is linked 
to inflammation-driven activation of pro-oncogenic signaling 
(NF-κB, STAT) and repression of important tumor suppressors, 
including 15-PGDH; thus, here we investigate epithelial cell sig-
naling in Smad4Tko mice. In Smad4Tko mice, colon thickness (colon 
weight divided by length, expressed as g/cm) was twice that of 
normal controls at 8 months of age (Figure 1A). Colon thickness 
can be influenced by edema, thus this is merely supportive of the 
histological and biochemical observations that we describe below. 
Cytokines and chemokines that promote colitis-associated colon 
tumor development include TNF-α, IL-6, IL-1, and CCL2 (7–9, 
35), through mechanisms that include regulation of epithelial 
Figure 1
Smad4Tko mice develop CAC. Biomarkers of dis-
ease progression were defined in wild-type and 
Smad4Tko (KO) mice at 3 and 8 months of age. 
(A) The colon weight per length of 3-month-old 
or 8-month-old wild-type and Smad4Tko mice. (B) 
Expression of proinflammatory cytokines (TNF-α, 
IL-1β, IL-6, and IFN-γ) from colon epithelial cells 
from wild-type or KO mice, as measured by 
RT-PCR. (C) Phosphorylation of STAT1, STAT3, 
and Iκb as well as expression of iNOS, COX-2, 
and 15-PGDH, as detected by Western blot. (D) 
Concentration of nitrate from sera of wild-type and 
Smad4Tko mice. Analyses at 3 months include 
wild-type mice (n = 4) and Smad4Tko mice (n = 5); 
analyses at 8 months include wild-type (n = 7) 
and Smad4Tko mice (n = 8). Results shown are 
representative of 4 separate experiments. 
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homeostasis and increased epithelial proliferation. The expres-
sion of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6 
and IFN-γ,  was markedly elevated in the colons of Smad4Tko mice 
at 8 months of age, relative to that in wild-type controls (Figure 
1B). We observed a temporal relationship between the progressive 
increase in the expression of these inflammatory cytokines and 
the activation of NF-κB, STAT1, or STAT3 in intestinal mucosal 
epithelia in Smad4Tko mice, as assessed by Western blot analysis. In 
young mice (3 months of age), there was no difference observed 
in p-STAT3, iNOS, COX-2, and 15-PGDH expression in wild-type 
and Smad4Tko mice, consistent with an absence of enhanced inflam-
matory cytokine expression at this age. The phosphorylation of 
STAT1 (activated by IFN-γ) was hardly detectable in the colons 
of wild-type mice but was greatly increased in Smad4Tko mice at 
8 months of age (Figure 1C). Overexpression of iNOS is a com-
mon phenomenon during chronic inflammation. While iNOS 
induction was not detected in wild-type mice, it was substantially 
increased in Smad4Tko mice (Figure 1C), strongly correlating with 
an elevated serum nitrate concentration in Smad4Tko mice, reaching 
a level 3 times greater than that in wild-type mice at 8 months of 
age (Figure 1D). Previous reports have shown that the constitu-
tive expression of 15-PGDH found in normal human colon mucosa 
is undetectable in human colon cancers (13). In our studies, both 
3-month-old wild-type and Smad4Tko mice had high expression of 
15-PGDH, but, by 8 months of age, the Smad4Tko mice invariably 
lost expression of 15-PGDH in colon mucosa (Figure 1C).
Daily oral administration of CDDO-Me suppresses colitis-associated 
colon tumorigenesis in Smad4Tko mice. There is increasing evidence 
that the triterpenoid family of small molecules (both natural 
and synthetic) target important signaling intermediates linked 
to inflammation and cancer (25). To test whether the synthetic 
triterpenoid CDDO-Me might serve as an effective chemopre-
ventive agent in the context of CAC, CDDO-Me was given orally 
to Smad4Tko mice and respective controls (250 ng per mouse per 
day, 3 times per week for 1 month), beginning at 8 months of 
age (see schema in Figure 2A). Smad4Tko mice receiving vehicle 
alone (sesame oil) were used as a control group. The survival of 
CDDO-Me–treated mice was 100% at 9 days from initiation of 
therapy and 80% at the end of the experimental period, compared 
with 60% and 10%, respectively, in the control group (Figure 2B). 
Decreased survival in control mice correlated with an 8% reduc-
tion in weight not observed in the CDDO-Me–treated groups (Fig-
ure 2C). Furthermore, Smad4Tko mice receiving sesame oil only 
(control group) displayed gross thickening and enlargement of 
small and large intestines, rectal prolapse, and multiple polyps 
(Figure 2D, images i and iii). Smad4Tko mice receiving CDDO-Me 
had very normal appearing intestines at gross necropsy (Figure 2D, 
images ii and iv). The colon weight per length (g/cm) of CDDO-
Me–treated mice (0.065 g/cm) was nearly fifty percent less than 
that of control mice receiving sesame oil alone (0.12 g/cm) (Figure 
2E). Sections of the intestines of Smad4Tko mice stained with H&E 
also clearly demonstrate a difference in histopathology between 
Figure 2
Oral administration of CDDO-Me 
suppresses mucosal inflammation 
in 8-month-old Smad4Tko mice. (A) 
Eight- month- old Smad4Tko mice 
were given CDDO-Me by gavage 
every other day for 1 month. (B) 
Mortality (n = 10 per group). (C) 
Percent weight change. (D) Colon 
histology (i and iii show sections 
from Smad4Tko mice receiving con-
trol sesame oil; ii and iv show sec-
tions from Smad4Tko mice treated 
with CDDO-Me). (E) Colon weight 
per length (g/cm) (n = 9). Error bars 
indicate SEM; *P < 0.05, **P < 0.01 
compared with mice in control group 
receiving sesame oil alone. 
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recipients of CDDO-Me or vehicle control (Figure 3A). Colon 
tumors were present in 92% of Smad4Tko mice. However, this tumor 
incidence decreased significantly to 25% in the CDDO-Me–treated 
group (Figure 3B). The multiplicity of colonic tumors (number 
of tumors per mouse) was significantly decreased in CDDO-Me–
treated mice (0.71 per mouse) when compared with that in mice 
receiving sesame oil alone (4.22 per mouse) (Figure 3C). Tumor size 
was also reduced by exposure to CDDO-Me (0.75 mm) relative to 
that in recipients of sesame oil alone (2.18 mm) (Figure 3, D and E). 
As anticipated, we found that the expression of proinflammatory 
mediators was not restricted to tumor tissue (Figure 3F), as the 
expression of p-STAT1, p-STAT3, COX-2, and p-iκB was similar in 
lysates of tumor and of adjacent intestinal mucosa.
Oral administration of CDDO-Me suppresses proinflammatory cytokine 
production and epithelial cell proliferation, while inducing expression of the 
tumor suppressor 15-PGDH. While triterpenoids exert direct antipro-
liferative effects, it is likely that suppression of mucosal epithelial 
cell proliferation by CDDO-Me in our model would be linked to 
suppression of inflammatory cytokine production and activation 
of downstream signaling intermediates, including STAT1, STAT3, 
NF-κB, and others (as shown in Figure 3F). Analysis of Ki-67– 
positive cells in the intestinal crypts showed that exposure to 
CDDO-Me significantly reduced epithelial cell proliferation in 
the colons of Smad4Tko mice when compared with that in recipients 
of sesame oil alone (Figure 4A). Production of proinflammatory 
cytokines, IL-6 and IFN-γ,  was substantially reduced by expo-
sure to CDDO-Me (Figure 4B) and correlated with a reduction 
in phosphorylation of STAT3 and STAT1 in colon epithelial cells 
in mice exposed to CDDO-Me (Figure 4C). When we examined 
the effects of CDDO-Me on the production of the inflammatory 
mediator iNOS, we found iNOS protein expression and mRNA 
transcript levels were greatly elevated in Smad4Tko mice receiving 
sesame oil alone when compared with iNOS levels observed in wild-
type mice and Smad4Tko mice exposed to CDDO-Me (Figure 4D).
Finally, we examined the relationship of exposure to CDDO-
Me to the expression of 15-PGDH (mRNA and protein) in 
colon epithelia of Smad4Tko mice. While neither 15-PGDH pro-
tein or mRNA were detected in the Smad4Tko recipients of ses-
ame oil alone, treatment with CDDO-Me for 1 month restored 
15-PGDH expression to levels matching those observed in healthy 
wild-type mice (Figure 4D). The serum nitrate concentration was 
also reduced in recipients of CDDO-Me (Figure 4E).
CDDO-Me suppresses DSS-induced colitis and AOM/DSS-induced 
colon carcinogenesis. Young Smad4Tko mice (at less than 3 months 
old) appear healthy and do not show indications of inflammation, 
such as high nitrate levels and production of proinflammatory 
cytokines, and they have no clinical symptoms of colitis. Thus, 
to develop this model further and to accelerate the onset of 
disease, we used DSS to induce inflammation in Smad4Tko mice. 
We exposed 8-week-old mice to 2% DSS in drinking water for 
7 days, followed by administration of regular water for 10 days. 
This cycle was repeated 3 times (Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI69672DS1). Exposure of Smad4Tko mice to 2% DSS resulted 
in a substantial increase in production of proinflammatory 
cytokines, such as IL-6 and IFN-γ, while Smad4Tko mice receiving 
only normal drinking water did not show any increase in produc-
tion of proinflammatory cytokines (Supplemental Figure 1B). 
Figure 3
Cancer chemoprevention by CDDO-Me in the Smad4Tko mouse model of CAC. (A) Mucosal histology was examined in Smad4Tko mice treated 
with either sesame-oil or CDDO-Me. Paraffin-embedded sections were stained with H&E. Scale bars: 200 μm. (B) Percentage of tumor-bear-
ing mice. (C) Tumor number. (D) Tumor sizes were determined using a digital eyepiece. (E) Histogram showing size distribution of tumors. 
(F) Expression of proinflammatory mediators in tumor and nontumor intestinal mucosa. Whole tumor specimens and adjacent mucosa samples 
were homogenized. iNOS, p-STAT3, p-STAT1, COX-2, p-iκB, and β-actin expression were measured by Western blot. N, nontumor intestinal 
mucosa; T, tumor tissue. ***P < 0.001.
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The phosphorylated forms of transcription factors STAT1 and 
STAT3, which are activated by IFN-γ and IL-6, were greatly 
increased in extracts of mucosal epithelia of DSS-treated Smad4Tko 
mice (Supplemental Figure 1C). At this time point, there was nei-
ther induction of TNF-α expression nor a significant change in 
activation of the TNF-α signaling intermediates observed. How-
ever, iNOS expression was considerably elevated in colonic epi-
thelia of DSS-treated Smad4Tko mice, in which the expression of 
the tumor suppressor 15-PGDH was also completely suppressed 
(Supplemental Figure 1C). Last, serum nitrate levels were elevated 
in Smad4Tko mice exposed to DSS (Supplemental Figure 1D).
To determine whether CDDO-Me might suppress induction of 
colitis by DSS in Smad4Tko mice, CDDO-Me (250 ng per mouse per 
day) was administered 3 times per week for 4 weeks (Supplemen-
tal Figure 2A). Histologic examination by H&E staining demon-
strated suppression of the mucosal thickening and inflammation 
in Smad4Tko mice by CDDO-Me treatment (Supplemental Figure 
2B), correlating with a complete suppression of the expression 
of proinflammatory cytokines, such as IL-6 and IFN-γ, and a 
major reduction in p-STAT1 and p-STAT3 in the colonic mucosa 
of Smad4Tko mice receiving CDDO-Me (Supplemental Figure 2, 
C and D). Similarly, CDDO-Me suppressed the production of 
iNOS and associated elevations in serum nitrate normally found 
in DSS-treated Smad4Tko mice (Supplemental Figure 2, D and E). 
Finally, the suppressed basal expression of 15-PGDH observed 
in Smad4Tko mice exposed to DSS was restored to baseline by the 
administration of CDDO-Me (Supplemental Figure 2D). This res-
toration of 15-PGDH expression may be secondary to reversal of 
the direct suppression of 15-PGDH expression by inflammatory 
cytokines, as suppression of 15-PGDH by TNF-α in the context 
of colitis has been suggested previously (20). Indeed, we showed 
suppression of 15-PGDH expression in cultured epithelial cells 
by IFN-γ in vitro (Supplemental Figure 3A). Direct suppression 
of Pgdh gene expression by IFN-γ and IL-6 was demonstrated by 
reporter assays, in which IFN-γ and IL-6 suppressed 15-PGDH- 
luciferase activity in cells transfected with a 15-PGDH promoter 
construct (Supplemental Figure 3B). CDDO-Me also suppressed 
the production of IFN-γ and IL-6 by activated T cells (Supple-
mental Figure 3C). However, our data, thus far, do not rule out the 
possibility that CDDO-Me might directly induce the expression of 
15-PGDH in epithelial cells.
To support the relevance of our findings in the Smad4Tko model, 
we examined the effects of CDDO-Me in the AOM/DSS inflamma-
tion-associated murine model of colon carcinoma. Mice (C57/BL6, 
ages 6–8 weeks) received intraperitoneal injections with 10 mg/kg 
AOM (NCI), followed by exposure to 2% DSS in drinking water 
for 7 days (Figure 5A). We repeated 3 cycles of 2% DSS, with 10 
days of normal drinking water provided between cycles. At the end 
of 3 cycles, mice were sacrificed. The experimental group received 
CDDO-Me on alternating days during DSS treatment, following 
the same protocol used for the treatment of Smad4Tko mice. Weight 
was measured daily during treatment, and colon tumors were 
Figure 4
CDDO-Me treatment suppresses inflamma-
tory mediators and increases the expres-
sion of 15-PGDH in colon mucosa. Eight-
month-old Smad4Tko mice were treated with 
either sesame oil or CDDO-Me (250 ng 
per mouse per day) for 1 month. (A) The 
percentage of Ki-67–positive cells among 
all colon epithelium cells was determined 
in mice treated with either sesame oil or 
CDDO-Me. Data represent average ± SEM 
(n = 9). ***P < 0.001 with direct compari-
son to Smad4Tko mice receiving sesame 
oil alone. Scale bar: 100 μM. (B) Expression 
of proinflammatory cytokines, IL-6 and IFN-γ, 
was measured by RT-PCR. (C) Expression 
of STAT1 and STAT3, phospho-STAT1, and 
phospho-STAT3 was measured by West-
ern blot (lanes were run on the same gel but 
were noncontiguous). (D) Protein and mRNA 
expression of iNOS and 15-PGDH were mea-
sured by Western blot and RT-PCR analy-
sis (lanes were run on the same gel but were 
noncontiguous). (E) Nitrate concentration in 
sera of Smad4Tko mice receiving either ses-
ame oil or CDDO-Me. Wild-type control mice 
also received sesame oil (n = 9). 
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enumerated at the time of sacrifice, as described in the Methods. 
Mice receiving CDDO-Me experienced less change in body weight 
compared with the sesame oil–treated group (Figure 5B). Repeated 
DSS administration causes chronic inflammation, thereby mim-
icking IBD and greatly enhancing the incidence of AOM-induced 
tumors (Figure 5C). CDDO-Me recipients showed marked pro-
tection from AOM/DSS-induced colon cancer (Figure 5, C and 
D). Colon length, which shrinks with stress, inflammation, and 
ulceration, was relatively well preserved in the experimental group 
(7.5 ± 0.2 cm) when compared with that of mice receiving sesame 
oil alone (5.8 ± 0.16 cm; Figure 5E) (P = 0.000002). The multiplicity 
of colon tumors in the CDDO-Me–treated group was also signifi-
cantly lower than that in sesame oil–treated group (Figure 5F).
Induction of 15-PGDH by the synthetic triterpenoid CDDO-Me in colon 
epithelial cells in vitro. To pursue potential molecular mechanisms 
mediating the cancer chemopreventive effects of CDDO-Me in 
our model of CAC, we examined the effects of CDDO-Me on the 
expression of 15-PGDH in the epithelial cell line, FET. Confluent 
cultures of FET cells were treated for 24 hours with increasing 
concentrations of CDDO-Me (10–300 nM), after which the levels 
of 15-PGDH protein and mRNA expression were determined by 
Western blot and by reverse transcription–PCR (RT-PCR) analysis, 
respectively. A dose-dependent induction of the expression levels 
of both 15-PGDH protein and mRNA transcripts by CDDO-Me 
was observed (Figure 6A). The induction of 15-PGDH peaked at 
48 hours after initiation of CDDO-Me treatment (Figure 6B). To 
determine the effects of CDDO-Me on the transcriptional reg-
ulation of 15-PGDH, we investigated the luciferase activity of a 
15-PGDH promoter-pGL3 gene reporter (a 2.2-kb 15-PGDH 
promoter construct) in FET cells after CDDO-Me treatment. We 
observed a 5-fold increase in 15-PGDH-pGL3 luciferase activity 
following exposure to 300 nM CDDO-Me when compared with 
control cultures (Figure 6C). These results indicate that CDDO-
Me can induce 15-PGDH expression through direct transcrip-
tional regulation. This dose-dependent induction of 15-PGDH 
expression paralleled a dose-dependent suppression of colon 
epithelial cell proliferation by CDDO-Me, as determined by thy-
midine incorporation (Figure 6D). Previous reports have demon-
strated the capacity of synthetic triterpenoids to augment the 
response to TGF-β (31, 36, 37). Therefore, one interpretation of 
our data might be that the observed induction of 15-PGDH by 
CDDO-Me is dependent on activation of TGF-β signaling.
SMAD-dependent induction of 15-PGDH expression by CDDO-Me. 
Previous reports have established 15-PGDH as a potential media-
Figure 5
Chemoprevention of AOM/DSS-induced colon cancer 
by CDDO-Me. Body weight and tumor number in mice 
treated with AOM/DSS or AOM/DSS plus CDDO-Me. 
(A) Experimental procedure used to induce colon 
cancer in C57BL/6 mice. After initial AOM injection 
(10 mg/kg), DSS was given in drinking water, followed 
by normal drinking water. Either CDDO-Me (250 ng 
per mouse per day) or sesame oil were given to the 
mice every other day during the DSS treatment. (B) 
Changes in body weight among each group were 
defined as follows: percentage = (final weight − initial 
weight)/initial weight × 100. CDDO-ME treatment did 
not affect the body weights. Tumors were enumerated 
examined using a dissecting microscope at day 53. 
(C) Images of colons at necropsy and (D) H&E stain-
ing of tumor morphology. Scale bar: 200 μM. (E) Colon 
length and (F) number of tumors in sesame oil–treated 
or CDDO-ME–treated groups. The sesame oil–treated 
group had 10 mice, and the CDDO-ME–treated group 
had 9 mice. Results are mean ± SEM. **P < 0.01. 
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tor of tumor suppression by TGF-β. In our studies, TGF-β (1 ng/
ml) increased expression of 15-PGDH in cultured colon epithelial 
cells, and this induction was augmented in a dose-dependent man-
ner by CDDO-Me (Figure 7A). The direct effect of CDDO-Me on 
TGF-β signaling is further demonstrated by the dose-dependent 
increase of SBE-luciferase reporter activity in FET cells exposed 
to CDDO-Me. TGF-β induction of SBE-luciferase activity was 
further potentiated by coadministration of CDDO-Me (Figure 
7B). Phosphorylation of the TGF-β receptor-activated interme-
diates, SMAD2 and SMAD3, was observed in FET cells following 
30 minutes of exposure to CDDO-Me (Figure 7C). To confirm that 
the induction of 15-PGDH by CDDO-Me is mediated by TGF-β 
signaling, we showed that pretreatment of FET cells with TGF-β 
receptor inhibitors (SB431542 and IN1130) blocked the induc-
tion of 15-PGDH expression by CDDO-Me, TGF-β, or the com-
bination in FET cells (Figure 7D). Similarly, the SMAD3-specific 
inhibitor, SIS3, blocked induction of 15-PGDH by either CDDO-
Me or TGF-β (Figure 7D).
Last, we explored the requirement for SMAD signaling for 
induction of 15-PGDH by CDDO-Me in vivo. Smad4Tko mice have 
an intact TGF-β signaling system in the mucosal epithelia. As pre-
dicted, administration of CDDO-Me (either 1.25 or 5 μg given 
by mouth, for a total of 2 doses) increased 15-PGDH expression 
in a dose-dependent manner in the 
colonic epithelia of Smad4Tko mice, 
as determined by Western blot 
analysis (Figure 7E). However, the 
administration of CDDO-Me to 
mice with a germ line deletion of 
the gene encoding the TGF-β sig-
naling intermediate, SMAD3, had 
no effect on 15-PGDH expression 
(Figure 7E). These results are con-
sistent with in vitro experiments 
and show that enhanced expres-
sion of 15-PGDH by CDDO-Me 
is mediated, at least in part, by 
activation of the TGF-β signaling 
pathway. Similarly, the suppression 
of FET cell proliferation by TGF-β 
is enhanced by coadministration of 
CDDO-Me, as determined by thy-
midine incorporation (Figure 7F).
Discussion
In this study, we have assessed the 
role of 15-PGDH as a mediator of 
the effects of a synthetic triterpe-
noid (CDDO-Me) in the suppres-
sion of colitis and colitis-associated 
colon carcinogenesis. Our data pro-
vide the first direct demonstration 
that CDDO-Me has specific and 
potent chemopreventive activity in 
CAC. We have observed a similar 
response to related triterpenoids 
(both natural and synthetic) in 
this model, suggesting that this is 
a property that extends to other 
members of this class of small mol-
ecules (data not shown). Mice lacking Smad4 gene expression in T 
cells (Smad4Tko mice) invariably develop inflammation in the colon, 
which progresses to CAC. This phenotype is linked to a significant 
production of proinflammatory mediators in colon epithelia. In 
our Smad4Tko mouse model, the observed increases of IFN-γ and IL-6 
lead to activation of STAT1 and STAT3 signaling and suppression 
of 15-PGDH expression in colon epithelial cells and to increased 
epithelial cellular proliferation. Oral administration of CDDO-Me 
markedly suppressed production of proinflammatory cytokines 
(IFN-γ and IL-6), a response linked to suppression of STAT1 and 
STAT3 activation. The proinflammatory mediator iNOS and its 
product NO were also suppressed by treatment with CDDO-Me.
The exploration of 15-PGDH as a therapeutic target has 
started to gain interest (38). While our studies have focused 
primarily on the role of 15-PGDH in suppressing colon carcino-
genesis, recent studies suggest that 15-PGDH plays an important 
role in gastric carcinogenesis as well (39). Gastric cancer cells sta-
bly transfected with a 15-PGDH siRNA plasmid have a higher 
rate of proliferation, while stable transfection with a 15-PGDH 
cDNA suppressed both growth rate, clone formation, and soft 
agar colony formation of gastric cancer cells in vitro as well as 
tumor formation in athymic nude mice in vivo (39). Agents that 
specifically activate the expression of 15-PGDH have not been 
Figure 6
CDDO-Me increases the expression of 15-PGDH in colon epithelial cells. (A) Expression of 15-PGDH 
protein and mRNA after treatment with CDDO-Me. FET cells were treated with various doses of CDDO-
Me (0–300 nM) for 24 hours. Expression of 15-PGDH protein and mRNA was analyzed by Western 
blotting and RT-PCR analysis (β-actin was used as a control). Lanes were run on the same gel but were 
noncontiguous. The data shown are representative of 6 independent experiments. (B) Time-dependent 
effect of CDDO-Me (100 nM) on 15-PGDH expression. FET cells were treated with CDDO-Me (100 nM) 
for 6, 12, 24, 48, and 72 hours and analyzed by Western blot. The data shown are representative of 
3 independent experiments. (C) CDDO-Me–induced 15-PGDH promoter luciferase activity. pGL3 and 
15-PGDH promoter activity in FET cells following stimulation with CDDO-Me (300 nM) for 24 hours. 
The fold induction of the relative levels of 15-PGDH transcripts was compared with that of untreated 
pGL3 transcripts. A dual luciferase assay was performed, and data shown are averages of triplicate 
independent measurements of Firefly/Renilla luciferase readings normalized to untreated controls. 
Data represent average ± SEM (n = 4–6). (D) CDDO-Me inhibited colon epithelial cellular proliferation 
in a dose-dependent manner. 5 × 103 FET cells were cultured with CDDO-Me (0–300 nM) in 96-well 
plates with treatment, and proliferation was assessed by incorporation of 3H-thymidine. 
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described. However, calcitriol (i.e., 1,25-dihydroxy-vitamin D, 
ref. 3, the hormonally active form of vitamin D) suppresses COX-2 
expression and induces expression of 15-PGDH, thereby reduc-
ing the levels of inflammatory prostaglandins in estrogen recep-
tor–positive breast cancer (40), and it has similar effects in pros-
tate cancer (41). The requirement for the 15-PGDH pathway in 
mediating the antiproliferative and tumor suppressor actions of 
calcitriol is an area for further investigation. Our data implicate 
Figure 7
Induction of 15-PGDH expression by CDDO-Me requires SMAD-dependent TGF-β signaling. (A) FET cells cultured with CDDO-Me plus TGF-β 
(1 ng/ml). Western blot is representative of 3 independent experiments (noncontiguous lanes were run on the same gel). Graphs represent the 
mean ± SEM of 4 independent sets of experiments. (B) FET cells transfected with SBE-luc were treated with CDDO-Me plus TGF-β (1 ng/ml). 
Results of a dual luciferase assay are shown as averages (triplicate independent measurements of Firefly/Renilla luciferase normal-
ized to untreated controls). Results are representative of 3 different experiments. (C) FET cells were treated with either TGF-β or CDDO-Me (for 
10 minutes to 9 hours) and phosphorylation of SMAD2 and SMAD3 was examined by Western blot. (D) Cells were incubated for 30 minutes with 
either TGF-β receptor inhibitors, SB431542 (10 μM) or IN1130 (10 μM), or SMAD3-specific inhibitor, SIS3 (10 μM), before adding TGF-β (1 ng/ml) 
and/or CDDO-Me (300 nM). Data represent 3 independent experiments (all noncontiguous lanes were run on the same gel). (E) CDDO-Me 
failed to induce mucosal 15-PGDH expression in vivo in SMAD3 KO mice. Mice received CDDO-Me (1.25 μg or 5 μg) by gavage, and colon 
epithelial scrapings were analyzed by Western blot 24 hours after the last dose (all noncontiguous lanes were run on the same gel). (F) Prolif-
eration of FET cells (with or without CDDO-Me and/or TGF-β) was measured by incorporation of 3H-thymidine. 
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application, as the Markowitz lab and others have reported that 
approximately 30% of human colorectal cancers have TGF-β type II 
receptor mutations and over half of all human colorectal cancers 
have signaling defects downstream of the receptors (18, 42, 43). 
However, it is important to note that this emerging class of cancer 
chemopreventive agents includes small molecules that are multi-
functional and thus not selective for a specific target. Indeed, the 
ability of the triterpenoids to directly impair STAT3 function, to 
block NF-κB and mTOR signaling, and to activate Nrf2 (49–51) 
may contribute directly to the observed clinical benefit noted in 
the models of CAC we describe (52). Indeed, the capacity to 
relieve repression of 15-PGDH by inflammatory mediators, such 
as IFN-γ and IL-6, represents a complementary mechanism that 
may work in tandem with direct SMAD-dependent activation of 
15-PGDH in epithelial cells.
The synthetic triterpenoid, CDDO, was developed initially 
through a small molecule screen for derivatives of oleanolic acid 
with an enhanced capacity to block induction of iNOS by 
IFN-γ (30). We have shown the imidazolide derivative of CDDO 
suppresses STAT3 activation and induces apoptosis in cancer cells 
(32). Here, we show in vivo administration of CDDO-Me effec-
tively blocks the induction of IFN-γ and IL-6, suppresses STAT1 
and STAT3 activation, and impairs induction of iNOS expression 
in models of CAC. Thus, our data add further evidence to support 
the relevance of the triterpenoid class of small molecules as agents 
with a capacity for cancer chemoprevention. Given the association 
among the loss of 15-PGDH expression, colon carcinogenesis, 
and celecoxib resistance, further preclinical development of nat-
ural triterpenes and related synthetic derivatives as cancer chemo-
preventive agents is clearly warranted.
Methods
Materials. CDDO-Me was synthesized by Reata Pharmaceuticals. Recom-
binant human TGF-β1 was purchased from R&D Systems. SB431542 and 
SIS3 were from Calbiochem. IL-6, IL-1, and TNF-α were obtained from 
Peprotech. Anti-SMAD3, anti-SMAD2, anti–phospho-SMAD2, and anti–
phospho-SMAD3 were purchased from Cell Signaling. The anti–15-PGDH 
antibody and 15-PGDH-pGL3 promoter vector were provided by Sanford D. 
Markowitz (Case Western Reserve University and University Hospitals, Cleve-
land, Ohio, USA). Monoclonal anti–15-PGDH antibody was raised in rabbits 
after injection of 15-PGDH protein purified from human placenta (13).
Animals and treatments. T cell–restricted deletion of the Smad4 gene in 
mice has been described previously (34). Mice (C57BL/6 × SvEv129 × FVB) 
homozygous for a SMAD4 conditional allele (Smad4co/co mice) (53) were bred 
with mice expressing a transgene encoding a Cre recombinase driven by the 
Lck promoter (Smad4co/co;Lck-cre mice) (54). Mice received 250 ng CDDO-Me 
orally every other day for 1 month. Body weight was measured, and mice were 
monitored for signs of rectal bleeding and diarrhea. After 4 weeks, mice were 
sacrificed, sections were taken from colons for histological assessment, and 
colon epithelial cell scrapings were taken for protein and RNA experiments.
For studies with DSS in this mouse model, 8-week-old SmadTko mice 
received 2% DSS (MP Biomedicals) in drinking water for 7 days, followed 
by regular drinking water for 10 days (repeated for 3 cycles). To deter-
mine whether CDDO-Me might suppress the development of colitis, after 
3 cycles of DSS treatment, 250 ng CDDO-Me was given 3 times per week 
by gavage for 4 weeks. For pathology, colon tissue samples were washed 
with PBS, cut longitudinally, and then formalin fixed and paraffin embed-
ded. For Western blot and RT-PCR analysis, epithelial cells were obtained 
from scrapings of full-length colons, which were immediately frozen at 
–80°C. All experiments were performed with 4 to 8 mice per group.
15-PGDH as a potential mediator of tumor suppression by the 
SMAD-dependent TGF-β pathway.
There are likely multiple mechanisms leading to the loss of 
15-PGDH expression in mucosal epithelial tumors, including 
active suppression of PGDH gene transcription by proinflamma-
tory cytokines like IFN-γ and TNF-α. The loss of 15-PGDH 
expression may also result from impaired TGF-β signaling, a com-
mon event in colon and gastric cancers (42–44). While published 
data support the concept that 15-PGDH plays a direct role in con-
trolling epithelial cell proliferation and colony-forming capacity, 
it has also been suggested that disruption of 15-PGDH expression 
may be a required or important step for cancer cell adaptation to 
the hypoxic tumor microenvironment and may promote survival 
under the microenvironmental stress of glucose deprivation (11, 
15). Furthermore, there is also a link between tumor-induced 
immunosuppression and a deficiency of 15-PGDH expression, 
with loss of 15-PGDH in tumor-infiltrating myeloid cells leading 
to immune evasion (45). Perhaps the most convincing argument 
in support of the development of small molecule activators 
of 15-PGDH is the recognition that inactivation of 15-PGDH 
serves as an important mechanism of resistance to celecoxib che-
moprevention of colon tumors (46). Therefore, it is anticipated 
that agents capable of enhancing the expression of 15-PGDH 
may overcome resistance to celecoxib, creating a potential to 
achieve a greater cancer chemopreventive benefit at a lower dose 
of celecoxib. Studies focused on the potential synergistic effects 
of celecoxib and triterpenoids may support the development of 
a chemopreventive strategy that will combine these agents to 
achieve maximal efficacy.
In Smad4Tko mice, expression of 15-PGDH was most likely sup-
pressed in colon epithelial cells as a consequence of the soluble 
mediators secreted during progressive colon inflammation. For 
example, in mice with DSS-induced colitis, 15-PGDH was com-
pletely suppressed in the colonic mucosa. This observed reduc-
tion of 15-PGDH in Smad4Tko mice was reversible by treatment 
with CDDO-Me, and reexpression of 15-PGDH was also accom-
panied by a reduction in the mucosal inflammatory process. 
These results provide further evidence of the biological signifi-
cance of 15-PGDH in colitis and CAC and point to a role for 
15-PGDH as a key regulator of epithelial homeostasis during the 
mucosal inflammatory process.
TGF-β signaling also plays a prominent role in the mainte-
nance of mucosal epithelial and immune homeostasis. For exam-
ple, the TGF-β signaling pathway has been identified recently as 
a principal mediator of Wnt5a signaling, and both are required 
for crypt regeneration after mucosal epithelial injury in mice (47). 
TGF-β signaling is also known to protect against epithelial injury 
in response to inflammatory mediators (48). CDDO-Me has 
been shown to augment TGF-β signaling by potentiating phos-
phorylation of SMAD2/3 in various cells (31, 33, 36). We found 
that exposure of colon epithelial cells to CDDO-Me results 
in activation of SMAD2/3, suggesting that this triterpenoid aug-
ments an autocrine TGF-β signaling loop. Our observation that 
the induction of 15-PGDH by CDDO-Me was antagonized by 
inhibitors of the TGF-β receptor kinase or by a SMAD3-specific 
inhibitor further supports this hypothesis and points to the impor-
tance of this signaling pathway as a relevant target of the triterpe-
noid class of small molecules.
The putative link between triterpenoid activity and TGF-β sig-
naling may lead to questions regarding their potential clinical 
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ing buffer (TBST, 0.05% Tween-20), followed by incubation with buffer 
containing the primary antibody. Membranes were washed 3 times in 
TBST-Tween-20 buffer (0.05% Tween-20) and incubated for 1 hour at 
room temperature with the horseradish peroxidase–conjugated second-
ary antibodies. After washing the membranes, immunostaining was 
visualized by ECL. Films of scanned images were quantified using ImageJ 
software (developed at the National Institute of Mental Health, NIH).
Histology. Colons were removed, flushed with PBS, fixed in 10% for-
malin, and embedded in paraffin wax. Sections were stained with H&E 
and examined by light microscopy. Assessment of tumor number was 
performed in a blinded fashion. Tumor size was calculated using a digital 
eyepiece, and the greatest width of each tumor was measured and recorded.
FACS analysis. Cell suspensions were prepared from spleens and lymph 
nodes filtered through 40-μm nylon mesh. Erythrocytes were lysed using 
ACK lysis buffer (BioWhittaker), and cells were washed twice in RPMI 
1640 supplemented with 10% heat-inactivated FBS, 50 μM 2-Me, penicil-
lin, and streptomycin (GIBCO/Life Sciences). Viable cells were counted 
using trypan blue exclusion and a hemacytometer. Antibodies used in 
FACS analyses and in purification of pan T cells were purchased from 
BD Pharmingen. Pan T cells were isolated using a Pan T Cell Isolation 
Kit according to the manufacturer’s instruction (purity greater than 95%).
Statistics. Data are expressed as mean ± SEM. Statistical significance 
was determined by 1-way ANOVA with Tukey-Kramer multiple compar-
isons test. Fisher’s exact probability test was used for comparison of the 
incidence of lesions between the 2 groups. P values of less than 0.05 were 
considered significant.
Study approval. All animal experiments were performed in accordance 
with institutional guidelines and with approval of Institutional Animal 
Care and Use Committees at Case Western Reserve University.
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Assessment of neoplasia and colitis. The colon was excised from the ileoce-
cal junction to the anal verge, flushed several times with PBS (Gibco), 
and opened longitudinally. Gross examination was performed to mea-
sure colon length and to evaluate tumor size. In addition, the incidence 
(defined as number of mice with tumors per total mice in the group), the 
mean number of tumors per mouse ± SD, and the mean tumor volume in 
the group ± SD were calculated for each group. All colon tissue, including 
tumors, was processed for histopathological evaluation and further bio-
chemical analyses. All procedures were performed in a blinded manner.
Cell cultures and transient transfection and luciferase assay. The FET human 
colon carcinoma cell line was a gift of Michael Brattain, Eppley Institute, 
University of Nebraska, Lincoln, Nebraska, USA. Cells were cultured in 
MEM (Invitrogen) with 10% FBS (Germini) and glutamine (2 mg/ml) at 
37°C in 5% CO2. FET cells were seeded in 12-well plates at 1 × 105 cells per 
well in triplicate and transiently transfected with 0.2 μg SBE promoter 
vector or 2.5-kb 15-PGDH–PGL promoter vector and 20 ng CMV-renilla 
using LipofectAMINE Plus as a  transfection agent according to the man-
ufacturer’s instructions (Invitrogen). Approximately 24 hours after trans-
fection, cells were treated with either CDDO-Me (10–300 nM) or TGF-β 
(1 ng/ml) for 24 hours in medium. Luciferase activity was measured using 
the Promega Dual-Luciferase Assay Kit and a ML3000 Microtiter Plate Lumi-
nometer. Data shown represent the mean of 3 independent experiments.
Nitrite assay. NO levels were measured by photometric analysis by using 
a Nitrite/Nitrate Assay Kit (Cayman Chemical). Sera were centrifuged for 
45 minutes at 2,000 g through an ultrafilter (Centricon, Millipore). 
Nitrate in the supernatant was reduced to nitrite by incubation with 
nitrate reductase and NADPH at room temperature for 1 hour. Nitrite con-
centration in the reduced samples was measured by the Griess reaction 
and calculated by comparison with standard solutions of sodium nitrite 
prepared in saline solution after reduction of nitrate.
RT-PCR analysis. TRIzol reagent (Invitrogen) was used for the isolation 
of total RNA. For RT-PCR, the One-Step RT-PCR Kit (Invitrogen) was 
used according to the manufacturer’s instructions. Samples were normal-
ized with β-actin mRNA levels. PCR products were analyzed by agarose 
gel electrophoresis in the presence of ethidium bromide. The products 
of amplification were visualized with a UV transilluminator.
Western blotting. Confluent cells cultured in 6-well tissue culture plates 
were treated with CDDO-Me and/or TGF-β for 24 hours at 37°C. After 
treatment, cells were harvested and lysed by incubation in lysis buffer 
(150 mM NaCl, 20 mM Tris-Cl pH 7.5, 1 mM PMSF, 1 mM Na3VO4, 
25 mM NaF, 1% aprotinin, 10 μg/ml leupeptin) on ice for 30 min-
utes. 20 μg aliquots of protein were separated by electrophoresis in 
10% SDS/PAGE minigels, followed by electrophoretic protein transfer 
to nitrocellulose membrane (Invitrogen). Nonspecific binding of anti-
body was prevented by incubating the membranes for 1 hour in block-
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